Top Influenza Diagnostics Companies

Influenza Diagnostics Market size was valued at USD 1.1 Billion in 2023 and is poised to grow from USD 1.14 Billion in 2024 to USD 1.51 Billion by 2032, growing at a CAGR of 3.5% during the forecast period (2025-2032).

The Influenza Diagnostics market is undergoing greater regulatory scrutiny. Presently, companies spend considerable resources on clinical trials and submissions to meet regulatory requirements for diagnosing new tests. This may impose substantial pressure on the cost of developing novel influenza diagnostics technologies. Therefore, governments across the globe are developing regulations to manage the development and control the cost of testing. These regulations can significantly impact the things for the market and products will be affected for the development and adoption perspective. 'Thermo Fisher Scientific (US) ', 'Becton, Dickinson and Company (US) ', 'F. Hoffmann-La Roche AG (Switzerland) ', 'Hologic, Inc. (US) ', 'Abbott Laboratories, Inc. (US) ', 'DiaSorin (Italy) ', 'QIAGEN N.V. (Netherlands) ', 'Fujirebio Diagnostics, Inc. (Japan) ', 'Meridian Bioscience, Inc. (US) ', 'Luminex Corporation (US) ', 'Seegene Inc. (South Korea) ', 'Bio-Rad Laboratories, Inc. (US) ', 'Alere Inc. (US) ', 'GenMark Diagnostics, Inc. (US) ', 'Roche Diagnostics (Switzerland) ', 'BioMérieux SA (France) ', 'Cepheid (US) ', 'SD Biosensor (South Korea) ', 'Acon Laboratories, Inc. (US) ', 'Inverness Medical Innovations, Inc. (US)'

The rising global prevalence of influenza has surged the R&D activities for the accurate detection and diagnosis. Although the major concentration of research activities is targeted towards the development of a rapid and precise diagnosis of the influenza viruses, it will drive Influenza Diagnostics Market growth as well. In addition to this, the rising incidences of government initiatives against the outbreak of influenza, technological advancements, and the increasing incidences of cardiovascular diseases and diabetes will provide a further push to market growth. 

Increasing in the Reported Cases of Influenza: The global influenza diagnostics market is expected to experience growth due to the increased occurrence of influenza. According to the centers for disease control and prevention on average about 12,000- 79,000 people die of Influenza each year in the United States. The market is also expected to grow during the forecast period because of the increasing awareness of the importance of early detection and prevention of diseases such as influenza. 

North America is dominating the Influenza Diagnostics market with the largest market share. The North American region dominated the diagnostic market in 2023 which was mainly due to the government’s support for high-quality healthcare, increase in focus of influenza outbreak, and the high buying power. The U.S. was the largest revenue contributor to the North American market in 2023. This is mainly because the U.S. market is expected to grow due to the well-established healthcare infrastructure and increase in programs for influenza diagnostics. These factors are increasing the growth of the influenza diagnostics market in the North America region.